Compare Citius Pharmaceuticals Inc (CTXR) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Jumia Technologies AG - ADR — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Jumia Technologies AG - ADR trades at $6.28 (market cap $865.90M). The key difference: Jumia Technologies AG - ADR is far larger — about 63.6× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 1,695,227). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Jumia Technologies AG - ADR for 28 Days on average.
| CTXR | JMIA | |
|---|---|---|
Market Cap | $13.62M | $865.90M |
Volume | 132,438 | 1,695,227 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $14.60 |
52-Week Low | $0.48 | $5.69 |
Typical Hold Time | 17 Days | 28 Days |
Enterprise Value | $3.79M | $831.54M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
JMIA trades at $6.48, down 3.86% today, with a bearish technical signal from moving averages. The company shows improving fundamentals, with revenue growing to $189M in 2025 and a narrowing net loss of -$62M, while maintaining a high gross margin of 56.33%. Recent news highlights a $50M capital raise and progress toward EBITDA breakeven by year-end 2026.
Analyst consensus is bullish with a $12.00 price target, but risks include persistent losses, high P/B ratio of 975.11, and negative cash flow from operations. The path to profitability remains the critical factor for investor returns, with execution on cost control and growth key to unlocking upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
